You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
|
|---|---|
| Published in |
Journal of Clinical Oncology, January 2023
|
| DOI | 10.1200/jco.22.02823 |
| Pubmed ID | |
| Authors |
Luis Paz-Ares, Stephane Champiat, W. Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa L. Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemi Reguart, Tatsuya Yoshida, Kai He, Shirish M. Gadgeel, Enriqueta Felip, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek K. Owonikoko |
X Demographics
The data shown below were collected from the profiles of 67 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 23 | 34% |
| France | 4 | 6% |
| United Kingdom | 2 | 3% |
| Spain | 2 | 3% |
| Greece | 1 | 1% |
| Turkey | 1 | 1% |
| Colombia | 1 | 1% |
| Canada | 1 | 1% |
| Nigeria | 1 | 1% |
| Other | 1 | 1% |
| Unknown | 30 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 41 | 61% |
| Practitioners (doctors, other healthcare professionals) | 15 | 22% |
| Scientists | 10 | 15% |
| Science communicators (journalists, bloggers, editors) | 1 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 90 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 17% |
| Other | 8 | 9% |
| Student > Ph. D. Student | 6 | 7% |
| Student > Postgraduate | 4 | 4% |
| Professor | 3 | 3% |
| Other | 12 | 13% |
| Unknown | 42 | 47% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 23% |
| Biochemistry, Genetics and Molecular Biology | 11 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Immunology and Microbiology | 3 | 3% |
| Agricultural and Biological Sciences | 2 | 2% |
| Other | 5 | 6% |
| Unknown | 42 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 727. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2024.
All research outputs
#28,620
of 25,935,829 outputs
Outputs from Journal of Clinical Oncology
#25
of 22,326 outputs
Outputs of similar age
#791
of 479,059 outputs
Outputs of similar age from Journal of Clinical Oncology
#3
of 349 outputs
Altmetric has tracked 25,935,829 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,326 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 479,059 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 349 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.